Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

732 Views

Poster Session: New Vaccines

2139 - Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Virtual

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Co-Author(s)

RC

Reynaldo Chandler, MD

CAENSA clinical trials
Panamá city, Panama, Panama

Presenting Author(s)

Nathali Montenegro, MD

Dr
Centro de Vacunación e Investigación CEVAXIN S.A., Avenida México
Panamá city, Panama, Panama

Co-Author(s)

CL

Cecilia Llorach, MD

Dr
Unidad Local de Atención Primaria de Salud de San Cristóbal, Caja de Seguro Social, Panamá; Instituto de Investigaciones Científicas y Servicios de Alta Tecnología AIP (INDICASAT AIP), Panamá
Panama City, Panama, Panama
DQ

Dean Quinn, MD

P3 Research
Wellington, Wellington, New Zealand
LN

Lorena Noriega-Aguirre, MD, ScD

Centro de diagnóstico y tratamiento de enfermedades respiratorias, CEDITER
Panamá city, Panama, Panama
MB

Mohammed Bensellam, PhD

GlaxoSmithKline Biologicals
Wavre, Brabant Wallon, Belgium
ND

Nathalie De Schrevel, PhD

Clinical Readout Team Leader
GSK, Rixensart, Belgium
Rixensart, Brabant Wallon, Belgium
SK

Sherine Kuriyakose, MSc

GlaxoSmithKline
Bangalore, Karnataka, India
AL

Axel Lambert, MSc

GlaxoSmithKline Biologicals
Wavre, Brabant Wallon, Belgium
AO

Aurélie Olivier, PhD

GlaxoSmithKline Biologicals
Wavre, Brabant Wallon, Belgium
VH

Veronica Hulstrøm, PhD MD

GSK, Wavre, Belgium
Wavre, Brabant Wallon, Belgium